Physician profile
John Nicasio
NPI 1982803003
$29,654.82
in general payments reported to CMS, 2019-2025
16 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $1,228 · 2022: $129 · 2023: $55.50 · 2024: $158 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16,095.71 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Regeneron Pharmaceuticals, INC. | $5,257.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $4,599.08 | 2019-2020 | |
| Valeritas, INC. | $2,630.98 | 2019 | |
| Zealand Pharma US, INC. | $300.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $147.68 | 2023-2025 | Eliquis, Camzyos |
| Corcept Therapeutics | $120.23 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $117.59 | 2022 | |
| Amgen INC. | $88.26 | 2020 | |
| Insulet Corporation | $81.16 | 2025 | Omnipod |
| Dexcom, INC. | $77.76 | 2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $59.40 | 2019 | |
| Abbott Laboratories | $28.85 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $24.66 | 2025 | |
| Cequr Corporation | $14.17 | 2023 | Cequr Simplicity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nicasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.